newsfilter
← Latest News
Business Wire·

Personalis Reports Second Quarter 2025 Financial Results

Strong Q2 Clinical Momentum with 59% Sequential Growth in Test Volume Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended